AiCuris’ Licensee MSD launches PREVYMIS™ (letermovir) in Germany

February 23, 2018
AiCuris Anti-infective Cures GmbH

Wuppertal, Germany, February 23, 2018 - AiCuris Anti-infective Cures GmbH, a leading company in the discovery and development of drugs against infectious diseases, today announced that MSD (in the U.S. and Canada known as Merck & Co., Inc., Kenilworth, N.J., USA), has launched PREVYMIS™ (letermovir) in Germany. PREVYMIS™, that was successfully developed by AiCuris up to clinical phase 2b and licensed to MSD in 2012, has recently been approved by the U.S. and European regulatory authorities for prophylaxis (prevention) of cytomegalovirus (CMV) reactivation and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT).

Press Release available here: